Bicycle Therapeutics (BCYC)
(Delayed Data from NSDQ)
$7.54 USD
-0.04 (-0.53%)
Updated Sep 25, 2025 04:00 PM ET
After-Market: $7.54 0.00 (0.00%) 6:22 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Fundamental Charts
About Return on Equity (TTM)
Bicycle Therapeutics PLC Sponsored ADR's return on equity, or ROE, is -32.43% compared to the ROE of the Medical - Biomedical and Genetics industry of -66.95%. While this shows that BCYC has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
BCYC 7.54 -0.04(-0.53%)
Will BCYC be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for BCYC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BCYC
Entrada Therapeutics (TRDA) Soars 5.6%: Is Further Upside Left in the Stock?
Bicycle Therapeutics (BCYC) Soars 5.7%: Is Further Upside Left in the Stock?
BCYC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for BCYC
BCYC Crossed Above 50 Day Moving Average on September 24
Is BCYC showing upside potential? 20 Day Moving Average Support shows up after declining 0.56%
Is BCYC poised for gains? Crossed Above 20 Day Moving Average shows up after advancing 2.89%
Fell Below 20 Day Moving Average appears for BCYC after 3.21% move
Is BCYC positioned for a breakout? Crossed Above 20 Day Moving Average shows up after climbing 3.47%